DBV Technologies S.A. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DBVT Nasdaq 2834 www.dbv-technologies.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for DBV Technologies S.A.

Information regarding the total number of voting rights and  total number of shares of the Company as of April 30, 2025 - May 6th, 2025 8:30 pm
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference - May 5th, 2025 8:30 pm
DBV Technologies Reports First Quarter 2025 Financial Results - Apr 30th, 2025 8:00 pm
Why DBV Technologies S.A. (DBVT) is Surging in 2025 - Apr 30th, 2025 10:25 am
DBV Technologies announces filing of 2024 Annual Report on Form 10-K and Universal Registration Document - Apr 11th, 2025 8:30 pm
Novo gains Lexicon obesity drug; CRISPR COO to step down - Mar 28th, 2025 11:01 am
DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved - Mar 28th, 2025 2:30 am
DBV Technologies Secures Agreement with FDA on Safety Exposure Data Required for BLA for Viaskin® Peanut Patch in 4–7-year-olds, Accelerating the Timeline for a BLA Filing Submission to 1H 2026, & Reports 2024 Unaudited Financial Results... - Mar 24th, 2025 6:30 am
DBV Technologies to Participate in Upcoming AAAAI/WAO Joint Congress - Feb 25th, 2025 9:01 pm
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - Jan 13th, 2025 9:05 pm
DBV Technologies Announces Positive 3-Year Results from EPITOPE Phase 3 Open-Label Extension Study - Jan 8th, 2025 9:05 pm
DBV Aligns With FDA On Accelerated Approval For Viaskin Peanut Patch In Younger Kids - Dec 12th, 2024 2:59 pm
DBV Confirms Alignment with U.S. FDA on Accelerated Approval Pathway for the Viaskin® Peanut Patch in Toddlers 1 – 3 Years-Old - Dec 11th, 2024 9:05 pm
Information regarding the total number of voting rights and  total number of shares of the Company as of November 30, 2024 - Dec 2nd, 2024 9:30 pm
DBV Technologies Announces Plan to Implement ADS Ratio Change - Nov 11th, 2024 9:30 pm
DBV Technologies’ stock slides as financial woes worsens - Nov 7th, 2024 5:07 pm
DBV Technologies Reports Third Quarter 2024 Financial Results - Nov 6th, 2024 9:30 pm
DBV Technologies price target raised to $7 from $5 at H.C. Wainwright - Oct 24th, 2024 12:31 pm
DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and Europe - Oct 22nd, 2024 8:45 pm
DBV Technologies to Participate in Upcoming ACAAI 2024 Congress - Oct 18th, 2024 8:30 pm